Abstract
The discovery of new biomarkers is a rapidly advancing area in cancer biology. The challenge of biomarker development for broad clinical use requires the translation of lab-based knowledge into clinical practice. The Long Interspersed Nuclear Elements-1 (LINE-1s or L1 elements) are active members of an autonomous family of non-LTR retrotransposons and occupy nearly 17% of the human genome. There is strong experimental evidence that the global hypomethylation of genomic DNA in cancer cells results in the activation of L1s and their expression is detectable at genome, transcriptome and proteome levels in human cancer cells. Thus, human L1s constitute a potential marker for cancer cells. In this review we have attempted to scrutinize L1 expression profiles in clinical cancer studies by undertaking a comprehensive systematic analysis of papers published in the field so far with a view to providing a more complete picture of the detection methods used, improvements achieved and potential future directions. Ultimately, we will try to evaluate the potential of L1s as a molecular marker in cancer detection.
Keywords: Human, LINE-1, L1 element, retrotransposon, cancer, biomarker, detection, screening techniques, genome, remnants, reverse transcriptase, junk DNA, polymorphism, mutagenesis, anticancer therapy
Current Molecular Medicine
Title: The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Volume: 11 Issue: 4
Author(s): O. Piskareva, W. Lackington, D. Lemass, C. Hendrick, P. Doolan and N. Barron
Affiliation:
Keywords: Human, LINE-1, L1 element, retrotransposon, cancer, biomarker, detection, screening techniques, genome, remnants, reverse transcriptase, junk DNA, polymorphism, mutagenesis, anticancer therapy
Abstract: The discovery of new biomarkers is a rapidly advancing area in cancer biology. The challenge of biomarker development for broad clinical use requires the translation of lab-based knowledge into clinical practice. The Long Interspersed Nuclear Elements-1 (LINE-1s or L1 elements) are active members of an autonomous family of non-LTR retrotransposons and occupy nearly 17% of the human genome. There is strong experimental evidence that the global hypomethylation of genomic DNA in cancer cells results in the activation of L1s and their expression is detectable at genome, transcriptome and proteome levels in human cancer cells. Thus, human L1s constitute a potential marker for cancer cells. In this review we have attempted to scrutinize L1 expression profiles in clinical cancer studies by undertaking a comprehensive systematic analysis of papers published in the field so far with a view to providing a more complete picture of the detection methods used, improvements achieved and potential future directions. Ultimately, we will try to evaluate the potential of L1s as a molecular marker in cancer detection.
Export Options
About this article
Cite this article as:
Piskareva O., Lackington W., Lemass D., Hendrick C., Doolan P. and Barron N., The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions, Current Molecular Medicine 2011; 11(4) . https://dx.doi.org/10.2174/156652411795677954
DOI https://dx.doi.org/10.2174/156652411795677954 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology The Therapeutic Potential of ADAM15
Current Pharmaceutical Design The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Opportunities and Challenges of Fluorescent Carbon Dots in Translational Optical Imaging
Current Pharmaceutical Design A New Approach to Locate the Gallbladder from Ultrasound Image Using Intensity Stretching and SOM-based Color Quantization
Current Medical Imaging The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design In Search of Natural Remediation for Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Chemotherapy in Addition to Preoperative Radiotherapy in Locally Advanced Rectal Cancer – A Systematic Overview
Reviews on Recent Clinical Trials Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy The Capsaicin Paradox: Pain Relief by an Algesic Agent
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Comparison of the Structure and Biological Activities of Wild-type and Mutant Liver-targeting Peptide Modified Recombinant Human Endostatin (rES-CSP) in Human Hepatocellular Carcinoma HepG2 Cells
Protein & Peptide Letters VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry The Shape of the Messenger: Using Protein Structure Information to Design Novel Cytokine-based Therapeutics
Current Pharmaceutical Design Magnetic Nanoparticles as Both Imaging Probes and Therapeutic Agents
Current Topics in Medicinal Chemistry The Role of Proteomics in Osteoarthritis Pathogenesis Research
Current Drug Targets